Inebilizumab, a B Cell-Depleting Anti-CD19 Antibody for the Treatment of Autoimmune Neurological Diseases: Insights from Preclinical Studies

Exaggerated or inappropriate responses by B cells are an important feature in many types of autoimmune neurological diseases. The recent success of B-cell depletion in the treatment of multiple sclerosis (MS) has stimulated the development of novel B-cell-targeting therapies with the potential for i...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Ding, Gallagher, Sandra, Monson, Nancy L., Herbst, Ronald, Wang, Yue
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2016
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5184780/
https://www.ncbi.nlm.nih.gov/pubmed/27886126
http://dx.doi.org/10.3390/jcm5120107

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5184780/
https://www.ncbi.nlm.nih.gov/pubmed/27886126
http://dx.doi.org/10.3390/jcm5120107

Ejemplares similares